MedAdvisor Future Growth
Future criteria checks 4/6
MedAdvisor is forecast to grow earnings and revenue by 119.5% and 16.6% per annum respectively. EPS is expected to grow by 121.5% per annum. Return on equity is forecast to be 11.6% in 3 years.
Key information
119.5%
Earnings growth rate
121.5%
EPS growth rate
| Healthcare Services earnings growth | 24.7% |
| Revenue growth rate | 16.6% |
| Future return on equity | 11.6% |
| Analyst coverage | Low |
| Last updated | 03 Jun 2024 |
Recent future growth updates
Recent updates
Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Jun 26
Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S
Apr 24Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?
Mar 20Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Dec 15Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Apr 20MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt
Jun 29Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now
Nov 09Is MedAdvisor (ASX:MDR) A Risky Investment?
Oct 11Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Mar 08MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain
Feb 10What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?
Jan 18
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares
Dec 22What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?
Dec 18Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation
Nov 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | 165 | 11 | 13 | 15 | 3 |
| 6/30/2025 | 144 | 3 | 8 | 9 | 3 |
| 6/30/2024 | 121 | 1 | 7 | 7 | 3 |
| 12/31/2023 | 109 | -9 | -7 | -6 | N/A |
| 9/30/2023 | 104 | -10 | -4 | -4 | N/A |
| 6/30/2023 | 98 | -11 | -2 | -1 | N/A |
| 3/31/2023 | 96 | -8 | 7 | 7 | N/A |
| 12/31/2022 | 93 | -5 | 16 | 16 | N/A |
| 9/30/2022 | 80 | -11 | 8 | 8 | N/A |
| 6/30/2022 | 68 | -17 | -1 | 0 | N/A |
| 3/31/2022 | 66 | -16 | -6 | -5 | N/A |
| 12/31/2021 | 64 | -14 | -11 | -11 | N/A |
| 9/30/2021 | 52 | -14 | -12 | -12 | N/A |
| 6/30/2021 | 39 | -14 | -13 | -13 | N/A |
| 3/31/2021 | 28 | -13 | -10 | -9 | N/A |
| 12/31/2020 | 18 | -12 | -6 | -6 | N/A |
| 9/30/2020 | 14 | -11 | -8 | -7 | N/A |
| 6/30/2020 | 10 | -10 | -9 | -9 | N/A |
| 3/31/2020 | 9 | -9 | -9 | -8 | N/A |
| 12/31/2019 | 9 | -9 | -8 | -8 | N/A |
| 9/30/2019 | 9 | -8 | -8 | -7 | N/A |
| 6/30/2019 | 8 | -8 | -7 | -7 | N/A |
| 3/31/2019 | 8 | -7 | -6 | -6 | N/A |
| 12/31/2018 | 7 | -7 | -6 | -5 | N/A |
| 9/30/2018 | 7 | -6 | -5 | -4 | N/A |
| 6/30/2018 | 7 | -4 | -4 | -3 | N/A |
| 3/31/2018 | 6 | -4 | -5 | -3 | N/A |
| 12/31/2017 | 6 | -4 | -6 | -3 | N/A |
| 9/30/2017 | 5 | -4 | N/A | -3 | N/A |
| 6/30/2017 | 4 | -3 | N/A | -2 | N/A |
| 3/31/2017 | 3 | -4 | N/A | -3 | N/A |
| 12/31/2016 | 2 | -4 | N/A | -3 | N/A |
| 9/30/2016 | 2 | -4 | N/A | -3 | N/A |
| 6/30/2016 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2016 | 1 | -2 | N/A | -2 | N/A |
| 12/31/2015 | 2 | -1 | N/A | -1 | N/A |
| 9/30/2015 | 2 | -1 | N/A | -1 | N/A |
| 6/30/2015 | 2 | -1 | N/A | 0 | N/A |
| 6/30/2014 | 1 | -1 | N/A | -1 | N/A |
| 6/30/2013 | 1 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MDR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDR is expected to become profitable in the next 3 years.
Revenue vs Market: MDR's revenue (16.6% per year) is forecast to grow faster than the Australian market (5.4% per year).
High Growth Revenue: MDR's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDR's Return on Equity is forecast to be low in 3 years time (11.6%).